Clinical trialsCompany release

Inhibikase reports Q3 loss of $20.5m as IKT-001 PAH Phase 3 trial expands

🇺🇸 Inhibikase Therapeutics, Inc. (IKT) · Tue 10 Nov 2026

The company says its Phase 3 IMPROVE-PAH study has approvals in 28 countries, 79 active sites and FDA orphan designation, with interim safety data due in the first half of 2027.

Inhibikase Therapeutics reported third-quarter 2026 results on 10 November, showing a net loss of $20.5 million and cash of $193.3 million.

The company's lead programme is IKT-001, an oral anti-proliferative being developed for pulmonary arterial hypertension (PAH). Its Phase 3 IMPROVE-PAH trial now has regulatory approvals in 28 countries. Of a planned 180 sites, 79 are active.

An interim safety readout from Part A of the study is planned for the first half of 2027.

In July 2026, the FDA's Office of Orphan Products Development granted IKT-001 Orphan Drug Designation. Inhibikase has also begun regulatory filings that would allow patients in Part B of the trial to receive IKT-001 in combination with sotatercept.

The full source text was not available for this report, so further details on trial design, enrolment numbers and financial guidance are not covered here.

What it means for your team

  • Multi-country approvals for IMPROVE-PAH show the trial is moving through national regulatory systems, with 79 of 180 planned sites now active.
  • The Part A interim safety readout, planned for the first half of 2027, is the next data milestone to watch.
  • Filings to permit sotatercept combination therapy in Part B may require additional regulatory review in participating countries.
  • Orphan Drug Designation from the FDA was granted in July 2026; it is a designation, not a marketing approval.

Company's press release (SEC filing): Inhibikase Therapeutics, Inc. ↗

Article written by VigiEye from the official source (Inhibikase Therapeutics, Inc.). Claims are the company's own. AI-assisted; check the source before acting.

More Clinical trials All →